Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pipeline Watch: 15 Approvals And 16 Phase III Trial Updates

Executive Summary

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.


The table above records the past week's major events that occurred in the late-stage pipeline during the past week (see table for relevant dates), created using Informa Pharma Intelligence’s Biomedtracker.

The table lists drugs at Phase II or above for which an important catalyst was recorded during the week, according to catalyst type, including clinical results, trial starts and approvals. Make use of the tabs, scroll button and search function to see each section.

Hyperlinks in the table take subscribers to the relevant event section of Biomedtracker where more details can be found, and to articles on the Scrip website where the event in question is explored and analyzed.

The change to Biomedtracker's Likelihood of Approval (LOA) metric, and the new LOA, are also included as a percentage for products where available. The LOA is based on Biomedtracker's view of the historical progress of drugs developed within a particular disease sector, combined with an opinion of its analysts.

A companion resource, the Pink Sheet's regulatory-focused FDA Performance Tracker, follows regulatory milestones such as marketing submissions, approvals, user fee dates and complete response letters.




Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts